Supplementary biomarker testing in molecular tumor boards increases actionable therapy recommendations: a prospective real-world study of 658 patients.
- DOI
- 10.1186/s12916-026-04636-y
- Published
- 2026 Jan 14
- Container
- BMC medicine
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1186/s12916-026-04636-y,
title = {Supplementary biomarker testing in molecular tumor boards increases actionable therapy recommendations: a prospective real-world study of 658 patients.},
author = {Scheiter A and Mellin S and Keil F and Meier J and Heudobler D and Brummer C and Einhell S and Zwicker B and Wutzlhofer E and Hierl F and Klemm S and Lüftl E and Schneider T and Perl M and Klier-Richter M and Immel A and Kaltofen T and Grube M and Bumes E and Seitz S and Schulz C and Haferkamp S and Drexler K and Troeger A and Steger F and Schlosser-Hupf S and Tews HC and Kandulski A and Wohlfart K and Erber R and Schönbuchner I and Lessel D and Schnabel MJ and Sedlmeier AM and Klinkhammer-Schalke M and Maurer J and Calvisi DF and Pukrop T and Kaiser U and Hirsch D and Dietmaier W and Evert M and Lüke F and Utpatel K},
year = {2026},
journal = {BMC medicine},
doi = {10.1186/s12916-026-04636-y},
url = {https://doi.org/10.1186/s12916-026-04636-y}
}RIS
TY - JOUR TI - Supplementary biomarker testing in molecular tumor boards increases actionable therapy recommendations: a prospective real-world study of 658 patients. AU - Scheiter A AU - Mellin S AU - Keil F AU - Meier J AU - Heudobler D AU - Brummer C AU - Einhell S AU - Zwicker B AU - Wutzlhofer E AU - Hierl F AU - Klemm S AU - Lüftl E AU - Schneider T AU - Perl M AU - Klier-Richter M AU - Immel A AU - Kaltofen T AU - Grube M AU - Bumes E AU - Seitz S AU - Schulz C AU - Haferkamp S AU - Drexler K AU - Troeger A AU - Steger F AU - Schlosser-Hupf S AU - Tews HC AU - Kandulski A AU - Wohlfart K AU - Erber R AU - Schönbuchner I AU - Lessel D AU - Schnabel MJ AU - Sedlmeier AM AU - Klinkhammer-Schalke M AU - Maurer J AU - Calvisi DF AU - Pukrop T AU - Kaiser U AU - Hirsch D AU - Dietmaier W AU - Evert M AU - Lüke F AU - Utpatel K PY - 2026 JO - BMC medicine DO - 10.1186/s12916-026-04636-y UR - https://doi.org/10.1186/s12916-026-04636-y ER -
APA
A, S., S, M., F, K., J, M., D, H., C, B., S, E., B, Z., E, W., F, H., S, K., E, L., T, S., M, P., M, K., A, I., T, K., M, G., E, B., S, S., C, S., S, H., K, D., A, T., F, S., S, S., HC, T., A, K., K, W., R, E., I, S., D, L., MJ, S., AM, S., M, K., J, M., DF, C., T, P., U, K., D, H., W, D., M, E., F, L., & K, U. (2026). Supplementary biomarker testing in molecular tumor boards increases actionable therapy recommendations: a prospective real-world study of 658 patients.. BMC medicine. https://doi.org/10.1186/s12916-026-04636-y
Source records
- pubmed · retrieved 2026-09-27T01:27:40.124Z